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The Hippo/YAP signaling pathway is a crucial
regulator of tissue growth, stem cell activity, and
tumorigenesis. However, the mechanism by which
YAP controls transcription remains to be fully eluci-
dated. Here, we utilize global chromatin occupancy
analyses to demonstrate that robust YAP binding
is restricted to a relatively small number of distal
regulatory elements in the genome. YAP occupancy
defines a subset of enhancers and superenhancers
with the highest transcriptional outputs. YAP modu-
lates transcription from these elements predomi-
nantly by regulating promoter-proximal polymerase
II (Pol II) pause release. Mechanistically, YAP inter-
acts and recruits theMediator complex to enhancers,
allowing the recruitment of the CDK9 elongating
kinase. Genetic and chemical perturbation experi-
ments demonstrate the requirement for Mediator
and CDK9 in YAP-driven phenotypes of overgrowth
and tumorigenesis. Our results here uncover the
molecular mechanisms employed by YAP to exert
its growth and oncogenic functions, and suggest
strategies for intervention.
INTRODUCTION
At the core of the Hippo pathway, a network of kinases controls
the subcellular localization of the transcriptional coactivator YAP
and its paralogue TAZ (Ramos and Camargo, 2012). YAP/TAZ
can translocate into the nucleus to activate gene expression by
associating with a number of DNA-binding transcription factors,
particularly of the TEAD family (Zhao et al., 2008). Ablation of
Hippo signaling or forced expression of constitutively active
YAP results in increased organ size, expansion of tissue pro-
genitor compartments, and, ultimately, occurrence of cancers
(Benhamouche et al., 2010; Camargo et al., 2007; Dong et al.,328 Molecular Cell 60, 328–337, October 15, 2015 ª2015 Elsevier Inc2007; Zhou et al., 2009). The remarkable effects of Hippo/YAP
on organ growth and its potential to crosstalk with multiple onco-
genic signaling cascades (Barry et al., 2013; Kapoor et al., 2014)
make this pathway a very attractive target for cancer therapeu-
tics. However, despite the tremendous importance of YAP/TAZ
in developmental and disease biology, major gaps in our mech-
anistic understanding of the transcriptional function of YAP
remain. For instance, it is still unclear where YAP, TAZ, and
TEADs bind in the genome of cancer cells, as is the identity of
the transcriptional complexes that are recruited by these factors
to drive gene transcription.
The transcriptional state of a specific cell type is determined
by the wiring of transcription factor networks that occupy a
variety of genomic elements dispersed throughout the noncod-
ing area of the genome. Such elements are able to impede
(named insulators) (Wendt et al., 2008), or to drive transcription
(named enhancers) of distal genes by recruiting a number of
cell-type-specific transcription factors (Calo and Wysocka,
2013). Enhancers are known to be the major determinants of
cell-type- and cancer-type-specific gene expression program
(Akhtar-Zaidi et al., 2012; Heintzman et al., 2009). More recently,
a very restricted subset of enhancers, named ‘‘superenhancers,’’
has been shown to drive higher transcription rate of genes that
define cell identity (Hnisz et al., 2013), and of key oncogenic
drivers in cancer cells (Love´n et al., 2013).
Mediator is a large multisubunit complex which binds to
enhancer elements and, together with the structural complex
cohesin, is involved in bringing distal elements in close proximity
to target promoters (Kagey et al., 2010). Mediator is able to
regulate both basal transcription driven by RNA Pol II as well
as recruitment of CDK9 to boost transcriptional elongation by
releasing Pol II promoter pausing (Malik and Roeder, 2010).
Such function, coupled to the binding of Mediator to a variety
of cell-type-specific transcription factors, allows Mediator to
integrate multiple signaling cues to deliver appropriate transcrip-
tional activation (Malik and Roeder, 2010).
Here we utilize multiple genomic technologies and biochem-
istry to provide a mechanistic insight into YAP/TAZ-driven
transcription. We demonstrate that in cancer cells, YAP/TAZ
occupy a very restricted number of TEAD positive enhancers.
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Figure 1. YAP Binds to Potent Enhancers
(A) Venn diagram of the common TEAD1/4 and YAP peaks in HuCCT1 cells.
(B) Scatterplot of the distance distribution of YAP peaks from the closest TSS in the indicated cell lines.
(C) Heatmap for the ChIP-seq signal of the indicated antibodies ±2 Kb from the center of YAP peaks. Clustering results from K-means method.
(D) Boxplots of the normalized counts of H3K27ac and H3K4me1 signal at YAP+ enhancer peaks or YAP enhancers. ***p < 0.0001.
(E) Boxplot indicating expression levels of genes associated to YAP+ or YAP enhancers following RNaseq in HUCCT1 cells.
(legend continued on next page)
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and superenhancers that drive very high transcriptional activity.
We find that YAP/TAZ predominantly control transcription of
their targets by modulating elongation of paused Pol II at pro-
moter regions. Additionally, we show that YAP/TAZ recruit the
Mediator complex in order to promote CDK9-dependent tran-
scriptional activity at target sites. Further, we provide evidence
demonstrating that the YAP-Mediator interaction and CDK9
activity are necessary for YAP-induced liver proliferation and
cancer growth. Our data provide a molecular mechanism
behind YAP-driven cell growth and tumorigenesis, and highlight
transcriptional control as a potential therapeutic strategy for
YAP-driven cancers.
RESULTS
YAP Predominantly Binds to a Restricted Number of
Putative Enhancer Elements
In order to characterize the molecular functions of YAP in tran-
scriptional regulation, we sought to analyze its genome-wide
occupancy by ChIP-seq. We chose to study liver cancer cell
lines given the spectacular effects of YAP on liver growth
and the general dependency of liver tumors on YAP activity
(Camargo et al., 2007; Dong et al., 2007). We optimized and per-
formed ChIP-seq for YAP using antibodies against the endoge-
nous protein (see Figure S1A available online), and also against
an epitope-tagged protein expressed at subendogenous levels
(Figures S1A and S1B). This analysis was done in two human
cholangiocarcinoma lines (HuCCT1 and Cclp1). We also per-
formed ChIP-seq for the two predominantly expressedmembers
of the TEAD family (TEAD1 and TEAD4) (Figure S1C). Our
strategy (see Experimental Procedures) identified 847 and 389
high-confidence binding sites for YAP in HuCCT1 and Cclp1
cells, respectively (Figures S1D–S1G). Unexpectedly, such bind-
ing sites represented only a very small fraction (7% and 4%,
respectively) of TEAD occupancy in the genome (Figures 1A,
S1H, and S1I). We also optimized ChIP-Seq for TAZ, which
revealed redundant patterns of occupancywithYAP (FigureS1J).
Thus, robust YAP/TAZ occupancy is associated only with a
very small subset of TEAD binding sites (Figures 1A and S1I),
in contrast to the widespread cobinding previously reported
(Zhao et al., 2008).
YAP transcriptional functions have been previously associated
to the binding of TEADs around the promoter of target genes
in embryonic stem cells (Lian et al., 2010). Similarly, studies in
Drosophila have demonstrated promoter-enriched binding for
the YAP ortholog, Yorkie (Oh et al., 2013). Yet, surprisingly, anno-
tation of YAP target loci revealed that YAP binds predominantly
20 Kb away from the closest transcriptional start site (TSS) (Fig-
ure 1B), suggesting instead binding to distal regulatory regions.
Indeed, clustering following ChIP-seq analysis for histone marks
revealed that the majority of YAP binding sites consisted of(F) Histogram indicating the fraction of YAP or YAP+ enhancers cataloged as r
(G) Line plots depicting H3K27Ac and H3K4me1 average signal in YAP+ enhanc
(H) Log2 changes in gene expression between siControl/siYT-treated cells for
Error bars represent 95% CI.
(I) Left panel, ChIP-qPCR for H3K27ac in selected YREs in cells at low and
these conditions. See also Figure S1.
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histone posttranslational modifications (H3K27ac+, H3K4me1+,
and H3K4me3) (Figure 1C). A few of these regions were
cloned into luciferase reporter vectors and their YAP-dependent
enhancer activity validated in transfection assays (Figure S2A).
Thus YAP/TAZ binding is restricted to distal regulatory elements
with enhancer features.
YAP Binding Defines a Subset of Highly Active
Enhancers and Superenhancers
We next asked whether the defined YAP-bound (referred as
YAP+) enhancer regions would have distinct features than
YAP enhancers similarly defined by double H3K27ac+ and
H3K4me1+ presence across the genome. Strikingly, YAP+ puta-
tive enhancer regions displayed a significantly higher density of
H3K27ac and H3K4me1 modification versus the average signal
at active enhancers not occupied by YAP (Figure 1D). Higher
density of such posttranslational modifications in histones
is typically associated with more robust enhancer activity. To
further support this idea, we used a proximity algorithm to assign
enhancers to their targets genes and performed RNaseq to
determine their expression levels. As predicted, this analysis
revealed that genes associated with YAP+ enhancers, as a
whole, were expressed at significantly higher levels than genes
linked to active YAP enhancers (Figure 1E). Thus, our data
indicate that YAP binding defines a subset of highly active
enhancers that drive potent expression of their target genes.
We will refer to these enhancers as YAP-bound regulatory
elements (YREs) hereafter.
The properties of the YREs are highly reminiscent of the
recently described superenhancers (Hnisz et al., 2013). We
thereby compiled a list of superenhancers in HuCCT1 cells
based on H3K27ac presence across the genome (Hnisz et al.,
2013). We find that approximately 25% of YREs are cataloged
as superenhancers in comparison to only 2% of YAP en-
hancers (Figure 1F). On the other hand, these YAP+ superen-
hancers represent approximately 17% of all superenhancers
in the cell, indicating that YAP/TAZ binding defines a distinct
subset of these elements (Figure 1F). Indeed, YAP occupancy
was associated with higher transcriptional outputs when com-
pared to YAP superenhancers (Figure S2B).
We next assessed whether the presence of YAP/TAZ was
required for YRE activity. To do so, we performed multiple
ChIP-Seq analyses and RNaseq following acute YAP/TAZ
knockdown (siYT) in HUCCT1 cells. We combined YAP and
TAZ manipulation given the highly overlapping genomic binding
patterns of both coactivators (Figure S1J). Silencing of YAP/TAZ,
indeed, resulted in reductions of H3K27ac+ and H3K4me1+
presence at YREs (Figures 1G, S2C, and S2D). Furthermore,
siYT also led to a concomitant loss of expression of genes asso-
ciated with both regular and superenhancer YREs (Figure 1H).egular or superenhancers in HuCCT1 cells.
ers upon siYT treatment.
genes associated with different genomic elements 48 hr post-transfection.
high density. Error bars, SD. Right panel, immunofluorescence for YAP in
.
Importantly, genes associated with YAP enhancers did not
exhibit changes in expression levels after siYT (Figure 1H). We
next tested whether YREs would be dynamic in their response
to upstream Hippo signaling. Indeed, H3K27ac+ presence at
YREs was reduced at high cell densities (Figure 1H), a condition
associated with Hippo signaling-driven YAP inactivation (Fig-
ure 1I) and reduction of target gene expression. Together, our
results indicate that YAP/TAZ binding defines a set of highly
active and dynamic enhancer elements in the genome, including
a subset of superenhancer driving the highest transcriptional
outputs, and that YAP/TAZ play a critical role in sustaining the
transcriptional program driven by these elements.
YAP Controls RNA Polymerase II Pause Release of
YRE-Associated Genes
Given the peculiar pattern of YAP binding at a restricted number
of enhancer elements, we next investigated the mechanisms by
which YAP/TAZ could regulate transcription fromYREs. First, we
tested the association between YAP/TAZ distal binding sites and
their computationally assigned promoters. We performed circu-
lar chromosome conformation capture (4C-seq) (van de Werken
et al., 2012), using 21 different YREs as anchors in HuCCT1 cells.
We generally observed that YREs assigned to target genes inter-
acted with their respective TSS and other enhancer regions,
indicating that YREs were indeed sites of long-range chromatin
interactions (Figure S2D and data not shown). However, upon
siYT, we observed minor or no differences in the interaction
frequency score of chromatin (Figure S2D), concluding that
YAP/TAZ are dispensable for normal chromatin looping.
Next, we examined the role of YAP/TAZ in regulating Pol II
recruitment and/or elongation, two major regulatory steps in
the transcriptional cascade (Wade and Struhl, 2008). To do
this, we determined the patterns of Pol II occupancy in genes
associated with YREs following siYT. While we observed reduc-
tion of Pol II density at the promoters of some YAP target genes,
the most drastic effect was the widespread loss of Pol II pres-
ence at gene bodies (Figure S3A), indicating impaired transcrip-
tional elongation. We utilized these genomic data to calculate
the Pol II pausing index (PI), otherwise known as the traveling
ratio (Adelman and Lis, 2012). This analysis revealed a significant
increase in the PI, indicative of impaired elongation, at YRE-
associated genes following siYT (Figure 2A). Further supporting
a key role for YAP in elongation, we show that YRE-associated
genes display significantly lower pausing than genes regulated
by non-YAP bound enhancers at steady state (Figure 2B).
Proximal Pol II pausing is an important and widespread mech-
anism to regulate elongation (Adelman and Lis, 2012). Recruit-
ment of the P-TEFb complex to paused promoters is one of
the rate-limiting steps for transcriptional pause release (Adelman
and Lis, 2012; Wade and Struhl, 2008). The core component
of P-TEFb, CDK9, catalyzes Pol II Serine 2 phosphorylation,
a mark that is associated with elongating, productive Pol II
throughout the gene body of active genes. If YAP/TAZ regulate
proximal pause release, then siYT would be predicted to cause
a reduction in the levels of Ser2-phosphorylated Pol II, but
should not affect the Ser5-Pol II phosphorylation (a marker of
initiation) (Adelman and Lis, 2012). Using ChIP-Seq analysis,
we found a significant change in Ser2 Pol II-density in the geneMolbody of YRE-associated genes, whereas Ser5 at the promoter
remained unaffected (Figures 2C–2E). Importantly, no changes
were evident in non-YAP target genes. Additionally, we, also
show that YRE-driven genes have significantly higher Ser2 Pol
II in their gene bodies compared to non-YAP target genes (Fig-
ures 2E and 2F). Our results demonstrate that YAP, by binding
to distal elements, confers higher transcriptional rate to its
targets by promoting RNA Polymerase II promoter release and
thereby its elongation.
YAP Recruits Mediator Complex at YRE to Drive
Transcriptional Activity
To provide insight into the molecular mechanisms employed by
YAP to control elongation we performed IP-mass spectrometry
studies. This analysis revealed the enrichment for different sub-
units of the Mediator complex (Figure S3B). Mediator is a large
protein complex known to integrate signals from transcription
factors in order to control multiple aspects of transcriptional acti-
vation (Malik and Roeder, 2010). Biochemical experiments vali-
dated the endogenous interaction between YAP and Mediator
subunit (Figure 3A) and demonstrated that these interactions
occurred onto chromatin (Figures S3C and S3D), and could
occur independent of TEAD binding (Figure S3E). Next, we
performed ChIP-seq for the MED1 subunit in HUCCT1 cells
and evaluated co-occupancy with YAP across the genome.
We found that >87% of YAP sites overlapped with MED1-bound
regions (Figures 3B and S3F), further supporting an important
functional interaction. Considering that there are more than
20,000 MED1 binding peaks in the genome, YAP/TAZ occu-
pancy represents a very small subset of MED1 sites, which
have some of the highest MED1 density (Figure 3C), even
when using as a comparison a size-matched data set of YAP
enhancers displaying equal levels of H3K27ac (Figure S3G).
We next asked whether YAP is required for Mediator occu-
pancy. Notably, siYT leads to a dramatic decrease of MED1
signal specifically around YREs (Figures 3B, 3C, S3H, and
S3J), with the degree of MED1 loss directly correlating to the
density of YAP binding at such sites (Figure 3D). YAP/TAZ are
selectively required for Mediator binding, as siYT does not affect
the occupancy of Cohesin, a known binding partner of Mediator
involved in establishing chromosome looping (Kagey et al., 2010)
(Figures 3B, 3C, and S3H). Mediator binding at YREs was dy-
namic and highly responsive to cell density cues, in contrast to
Cohesin occupancy, which remained unchanged at different
confluences (Figures 3E, S6J, and S6K). These experiments
demonstrate that YAP is necessary and sufficient to induce
Mediator recruitment to target sites, and reinforce our observa-
tions that YAP presence is important for enhancer activity, and
not for enhancer organization per se.
Our data point to Mediator recruitment by YAP as an essential
step for transcriptional activation of YAP target genes. We
thereby functionally tested Mediator function downstream of
YAP by silencing Mediator subunits in cells overexpressing a
doxycycline (Dox)-inducible constitutively active YAPS127A
allele. In mouse xenografts, silencing of Mediator results in
decreased growth (Figures 3F and S4A), as well as attenuation
of the activation of YRE associated genes (Figures S4B–S4D).
Collectively, our data demonstrate that the Mediator complexecular Cell 60, 328–337, October 15, 2015 ª2015 Elsevier Inc. 331
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Figure 2. YAP Controls RNA Polymerase II Promoter Pause Release
(A and B) Line graph representing the pausing index (PI) for YAP-positive genes upon YAP/TAZ silencing (siYT) (A) and YAP+ enhancer genes versus YAP (B).
(C) Boxplot representing the fold change of RNA Pol II pS5 at the promoter (pink shades) or pS2 in the gene body (green shades) in YAP+ and YAP- enhancer
genes upon siYT treatment.
(D) ChIP-seq tracks representing signal for RNA Pol II pS5 or pS2 around a representative YAP gene and a YAP+ gene.
(E) Metagene profile of RNAPol II pS5 (upper) and pS2 (lower) for YAP+ and YAP superenhancer genes in cells treated with siC and siYT.
(F) Boxplot showing the occupancy of Pol II pS5 at the promoter (pink shades) or pS2 in the gene body (green shades) in YAP+ and YAP enhancer genes. See
also Figure S2.is a functionally important downstream transducer of the YAP
transcriptional program.
CDK9 Activity Mediates YAP-Driven Transcriptional
Elongation
It has recently been demonstrated that Mediator, through its
head module, can act as a regulator of elongation by recruiting
P-TEFb (Donner et al., 2010;Wang et al., 2005). Thus, we posited
that YAP/TAZ promotes pause release by recruiting P-TEFb
through Mediator. Two pieces of evidence support this idea:
first, YRE-associated genes display higher levels of CDK9 occu-
pancy around their promoter (Figure 4A), and second, YAP target
genes display preferential loss of CDK9 upon siYT (Figure 4B).332 Molecular Cell 60, 328–337, October 15, 2015 ª2015 Elsevier IncTo explore the functional role of CDK9 downstream of YAP, we
used Flavopiridol (FP, a pan CDK inhibitor with selectivity toward
CDK9) along with the highly specific CDK9 inhibitor NVP-2
(Lu et al., 2015). These compounds are indeed able to rescue,
in a dose-dependent manner, the activation of YAP target
genes driven by a Dox-inducible YAPS127A transgene (Fig-
ure S4E). Transcriptional profiling of cells treated for 3 hr with
these two compounds demonstrates that YRE-associated
genes are particularly sensitive to inhibition of CDK9 (Figures
4C and S4F). This mechanism was corroborated in an animal
model, as 1 week FP administration results in a full rescue of
YAPS127A-driven increase in liver size and target gene expres-
sion (Figures 4D and S4G). In summary, these data demonstrate.
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Figure 3. YAP Recruits Mediator to Regulate Transcription
(A) Validation coIP between YAP-TEAD1 and MED12.
(B) ChIP-seq tracks of a YAP+ and YAP locus for YAP, MED1, and SMC1 in HuCCT1 cells treated with siC or siYT.
(C) Boxplot representing normalized MED1 (left) or SMC1 (right) coverage in YAP+ or YAP enhancers in siC- or siYT-treated cells.
(D) Scatterplot correlating YAP occupancy to loss of MED1 signal upon YAP/TAZ silencing. On the x axis, MED1 peaks are ranked according to YAP signal. y axis
in the top panel represents MED1 signal changes between siC and siYT cells. y axis in the lower panel represents the counts of YAP signal in each MED1 peak.
(E) ChIP-qPCR for MED1 and SMC1 at selected YREs in H69 cells at low and high density. Error bars, SD.
(F) Tumor volume of xenograft HuCCT1 bearing TetOYAP and/or shMED1 constructs relative to volume measured before the administration of Doxycycline
(n = 5 mice; error bars, SEM). See also Figure S3.
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Figure 4. YAP-Mediator Regulates Transcriptional Elongation via CDK9 Recruitment
(A) Normalized CDK9 coverage around the promoter of YAP-negative and YRE-associated genes. Error bars, 95% CI.
(B) Fold change of CDK9 occupancy upon siYT treatment around the promoter of YAP-negative and YRE-associated genes. Error bars, 95% CI.
(C) Log2 (FC) of expression of YAP versus YAP+ genes in HuCCT1 cells treated with CDK9 inhibitors Flavopiridol and NVP-2. Error bars, 95% CI.
(D) Liver/body weight ratio of mice overexpressing YAP for 1 week treated with vehicle or Flavopiridol.
(E) Model for YAP/Mediator-driven transcriptional elongation in active Hippo signaling (left) or inactive Hippo signaling (right). See also Figure S4.that YAP recruits the Mediator complex to YREs in order to drive
exceptionally high transcriptional activity via CDK9 recruitment
to mediate transcriptional pause release.
DISCUSSION
The Hippo/YAP signaling pathway has emerged as a tremen-
dously important regulator of stem cell biology and tumorigen-
esis. The mechanism by which YAP/TAZ control gene expres-
sion has remained an important open question in the field. Our
data provide evidence demonstrating that YAP/TAZ function is
predominantly restricted to the control of elongation of a rela-
tively small number of target genes. This has important implica-
tions for our conceptual understanding of Hippo signaling. Our
results imply that even when Hippo signaling is on (cytoplasmic
YAP/TAZ), their target loci still carry transcriptionally engaged
but proximally paused RNAPII (Figure 4E). Loss of Hippo-medi-334 Molecular Cell 60, 328–337, October 15, 2015 ª2015 Elsevier Incated regulation, and consequent YAP/TAZ nuclear relocation, al-
lows pause release via Mediator. We hypothesize that pausing
allows the rapid induction of gene expression in response to
physiological growth or regeneration cues, in a manner analo-
gous to the regulation of immediate early genes and inflamma-
tory responses (Adelman et al., 2009; Donner et al., 2010). Our
idea fits with the observation that knockout of YAP in the adult
results in the absence of phenotypes in many tissues at steady
state (Barry et al., 2013; Chen et al., 2014; Zhang et al., 2014),
whereas YAP is fully required for injury- or oncogene-driven
responses in those same tissues (Barry et al., 2013; Chen
et al., 2014; Zhang et al., 2014). Our data also suggest that
most YAP/TAZ targets in a cell would need to have engaged
Pol II, so that cell-type basal transcription would determine the
observed tissue specificity in YAP/TAZ targets.
The overall pattern of YAP binding in the genome of liver can-
cer cells is significantly distinct from what has been recently.
described in Drosophila (Oh et al., 2013, 2014), where YAP has
been found enriched at promoter regions (Oh et al., 2013). Our
results are not specific to the liver cancer cell lines used, as
TEAD binding has also been found to be highly enriched at
enhancer regions in two other cellular contexts (Beyer et al.,
2013; Cebola et al., 2015). We believe that such differences
might not be completely surprising, given some intrinsic differ-
ences between human and Drosophila genomes (Wilson and
Odom, 2009). Moreover, in terms of transcriptional effectors,
the Hippo pathway significantly differs in the mammalian system
compared to Drosophila. Indeed, four TEAD members exist in
mammals, whereas just one (Scalloped) exists in the fly. Such
evolutionary expansion could be due to an increase in the
complexity of transcriptional regulation in mammals, possibly
via the control of different sets of tissue-specific enhancer
elements.
Our analysis identifies a relatively small number of YAP binding
sites (Figure 1), which represent only a fraction of the TEAD
binding regions. These peaks represent robust and ‘‘high-confi-
dence’’ YAP-binding sites determined after application of a very
stringent analysis pipeline encompassing multiple negative
controls. While the number of YAP+ peaks found in our analysis
is significantly less than what has been described previously,
recent work in cardiomyocytes has identified1,300 YAP peaks,
which is in the range of the 850 sites detected by our method-
ology (Lin et al., 2015). However, it is important to consider that
since YAP does not bind DNA directly, its affinity and interaction
frequency for chromatin are likely to be lower than for a DNA-
binding transcription factor, such as TEAD. Thus, it is possible
that our analysis might miss a number of sites that may have
low levels of YAP bound. Still, one important insight regarding
the validity of our peak finding strategy can be obtained from
the analysis of functional consequences of YAP/TAZ knock-
down. If many other functionally relevant YAP+ sites would exist
outside of the 850 high-confidence peaks that we describe,
then siYT should result in loss of MED binding in those extra sites
as well. Importantly, our data demonstrate that most of MED1
loss occurs in the few hundred genes with highest YAP binding
(Figure 3D). Reduction in MED1 binding outside of this subset
of genes is negligible or barely above noise. These data indicate
that, at least in regards to MED binding, additional YAP sites that
we may have missed would represent sites of low functional
relevance.
Mechanistically, our results point to recruitment of Mediator
as the crucial step in YAP-driven transcription. The interaction
of YAP with Mediator has been described previously in human
embryonic stem cells (Varelas et al., 2008). Additionally, Yorkie
also forms a complex with Mediator in Drosophila, suggesting
the conservation of this interaction (Oh et al., 2013). Yorkie has
been shown to recruit a histone methyltransferase complex via
Ncoa6 (Oh et al., 2014), a subunit of the Thritorax-related (Trr)
methyltransferase complex. While we did not observe peptides
for any Trr complexmembers in ourmass spectrometry analysis,
it has been previously reported that Mediator can exist in com-
plex with mammalian Ncoa6 (Ko et al., 2000); thus YAP could still
be recruiting mammalian histone methyltransferase activity to
its target sites. The fact that we observe a significant loss of
H3K4me1 upon siYT also suggests that this might be the case.MolFurthermore, knockdown of Ncoa6 in H69 cells resulted in the
suppression of expression of two out of five YAP target genes
tested (Figure S4H). Thus, in this cellular context, Ncoa6 seems
to be functionally important for the expression of a subset of YAP
target genes. Future work should address whether recruitment
of histone methyltransferase activity, and other chromatin re-
modeling activity (Skibinski et al., 2014), occurs indirectly via
Mediator or is independently regulated by YAP/TAZ.
Finally, our results significantly add to the emerging theme of
enhancer misregulation in cancer and disease (Akhtar-Zaidi
et al., 2012; Chapuy et al., 2013; Love´n et al., 2013). In contrast
to other regulators of enhancer activity, which bind most ex-
pressed genes within a cell (Akhtar-Zaidi et al., 2012; Chapuy
et al., 2013; Love´n et al., 2013), YAP/TAZ binding is predomi-
nantly restricted to enhancers associated with a only few
hundred genes that are critical for growth, making YAP/TAZ ideal
targets for cancer therapeutics. Still, our data demonstrate that
therapies based on elongation inhibitors could be of use for
YAP-driven tumors.EXPERIMENTAL PROCEDURES
Cell Lines and Transfections
HuCCT1 (parental and Flag-HA-YAP5SA expressing) cells were maintained
in RPMI containing 10%FBS, 13HEPES, and 13 L-glutamine. Cclp1 (parental
and Flag-Bio-YAP5SA expressing) was maintained in DMEM containing
10% FBS. shRNAs, siRNAs, and compounds employed are detailed in the
Supplemental Experimental Procedures.
Mouse Models
Tetracycline-inducible YAPS127A expression mice were previously described
(Camargo et al., 2007). Viral injections and xenograft assays are detailed in
Supplemental Experimental Procedures.
ChIP-seq and RNA-seq
Chromatin immunoprecipitation was performed essentially as previously
described (Galli et al., 2012) and is detailed in Supplemental Experimental
Procedures.
Libraries for ChIP-sequencing were generated by using NEBNext Ultra
DNA Library Prep Kit for Illumina (NEB) and barcoding added using NEBNext
Multiplex Oligos for Illumina (Index Primers Set 1) (NEB) according to the
manufacturer’s recommendation.
RNA-seq libraries were generated using TruSeq RNA Sample Prep Kit v2
(Illumina) according to the manufacturer’s recommendation. All the high-
throughput sequencing experiments were run on a Hi-seq2000 (Illumina)
sequencer at the Center for Cancer Computational Biology (Dana Farber
Cancer Institute, Boston). Bioinformatic analyses are detailed in Supplemental
Experimental Procedures.
4C-Sequencing
4C templates were prepared as described previously23. DpnII digestion was
used as the first restriction enzyme to generate high-resolution 3C template,
which was further trimmed with Csp6I, NlaIII, or BfaI. 4C primers were
design following the general consideration as described23. The primers car-
ried additional 50overhangs composed of adaptor sequences for Illumina
single-read sequencing. Samples were sequenced on a Hi-seq 2000 ma-
chine (Illumina).ACCESSION NUMBERS
Sequencing data were deposited in the Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo) under accession number GSE62275.ecular Cell 60, 328–337, October 15, 2015 ª2015 Elsevier Inc. 335
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, two tables, and Supplemental
Experimental Procedures and can be found with this article at http://dx.doi.
org/10.1016/j.molcel.2015.09.001.
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